Experiments
Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).
-
Has reproduction · 72
Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).
PMID 38897205 · PMC11293361 · Cell reports. Medicine · 2024 · 8 claims · 8 setups
Neoadjuvant sintilimab plus carboplatin/nab-paclitaxel is clinically feasible and tolerable in resectable EGFR-mutant NSCLC, with all 18 patients completing treatment and undergoing radical surgery.
-
Has reproduction · 73
Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance.
PMID 34779495 · PMC8611403 · Oncology reports · 2022 · 7 claims · 8 setups
NF1 is highly expressed in cetuximab-sensitive colorectal cancer cell lines (NCI-H508, Caco2) but weakly expressed in cetuximab-resistant lines (KM12C, SW480)
-
Full-text index only
PD-1 blockade plus tyrosine kinase inhibitor remodels the tumor microenvironment in advanced renal cell carcinoma.
PMID 41916996 · PMC13199584 · Nature communications · 2026 · 8 claims · 8 setups
Non-responders to TKI±ICI therapy show increased neutrophil infiltration and enrichment of SAA+ tumor cells after treatment.
-
Has reproduction · 30
Bacillus Calmette-Guérin Treatment Changes the Tumor Microenvironment of Non-Muscle-Invasive Bladder Cancer.
PMID 35311085 · PMC8930202 · Frontiers in oncology · 2022 · 8 claims · 8 setups
BCG therapy has bidirectional effects on tumor evolution and immune checkpoint landscape, with a significant reduction in neoantigen burden percentage in relapsed tumors
-
Full-text index only
Anti-CSF-1R therapy with combined immuno-chemotherapy coordinate an adaptive immune response to eliminate macrophage enriched triple negative breast cancers.
PMID 41484081 · PMC12858953 · Nature communications · 2026 · 8 claims · 8 setups
Combined low-dose CTX + anti-CSF-1R (SNDX-ms6352) is highly effective against aggressive metastatic Trp53-null TNBC models with high macrophage infiltration, producing complete tumor regression in claudin-low models.
-
Full-text index only
A longitudinal, multi-omic atlas reveals the emergence of a spatially organized immunosuppressive ecosystem in resistant melanoma.
PMID 41916292 · PMC13130630 · Cell reports. Medicine · 2026 · 8 claims · 8 setups
Resistant tumors undergo convergent evolution toward a shared, spatially organized immunosuppressive ecosystem despite genetic heterogeneity.
-
Full-text index only
Effects of two common polymorphisms in the 3' untranslated regions of estrogen receptor beta on mRNA stability and translatability.
PMID 19754929 · PMC2759954 · BMC genetics · 2009 · 8 claims · 4 setups
Breast tumor heterozygotes show a significant difference in relative mRNA levels between the two alleles of rs4986938
-
Full-text index only
Multimodal framework for the joint analysis of single-cell RNA and T cell receptor sequencing data predicts T cell response to cancer immunotherapy.
PMID 41820396 · PMC13121706 · Nature communications · 2026 · 8 claims · 7 setups
TRIM, a conditional multi-modal variational autoencoder integrating paired scRNAseq and scTCRseq data, predicts T cell clonality and transcriptional states at unmeasured tissue sites/timepoints.
-
Full-text index only
Single-cell analysis highlights the significance of malignant cell IFN/MHC-II for immunotherapy response in head and neck squamous cell carcinoma.
PMID 41923630 · PMC13130666 · Cell reports. Medicine · 2026 · 8 claims · 4 setups
A malignant cell subset expressing IFN-response and MHC-II genes (IFN/MHC-II) increases in proportion after pembrolizumab treatment and is associated with response
-
Full-text index only
Live-cell Pick-Seq (LiP-Seq): Interrogating ultra-rare mantle cell lymphoma persistent cells after CART19 therapy.
PMID 41855504 · PMC13234471 · Blood advances · 2026 · 8 claims · 7 setups
LiP-Seq is a novel platform combining multiplexed live-cell imaging and needle-based single-cell retrieval that enables transcriptomic profiling of ultrarare (down to 10^-6 frequency), viable persistent lymphoma cells
-
Has reproduction · 75
Allele-specific immune gene quantification and expression analysis in single-cell RNA-seq data.
PMID 41229397 · PMC12604667 · NAR genomics and bioinformatics · 2025 · 8 claims · 4 setups
scIGD is a Snakemake workflow that automates HLA allele-typing and allele-specific expression quantification from scRNA-seq data
-
Full-text index only
PRDM1+ Malignant Cells Mediate an Immunosuppressive Landscape and Resistance to Neoadjuvant Chemoradiotherapy and Immunotherapy in Esophageal Squamous Cell Carcinoma.
PMID 41556358 · PMC13042517 · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026 · 8 claims · 8 setups
A PRDM1+ malignant epithelial cell subcluster (Epi_C4) is enriched in NMPR patients and is associated with nICRT treatment resistance
-
Full-text index only
Single-Cell Multi-Tissue T Cell Clonal Dynamics Reveal Distinct Immune Coercion Landscapes in MSI and MSS Colorectal Cancer.
PMID 41898550 · PMC13027115 · International journal of molecular sciences · 2026 · 8 claims · 5 setups
Immunotherapy response in CRC is better explained by TCR clonal dynamics (expansion, migration, functional transitions) than by MSI status alone
-
Full-text index only
Single-Cell Lineage Tracing Uncovers Resistance Signatures and Sensitizing Strategies to FLT3 Inhibitors in Acute Myeloid Leukemia.
PMID 41270153 · PMC7618455 · Cancer research · 2026 · 8 claims · 8 setups
ReSisTrace single-cell lineage tracing identifies pre-resistant and pre-sensitive cell states to FLT3 inhibitors midostaurin and quizartinib in FLT3-ITD-positive MOLM-13 AML cells before treatment
-
Full-text index only
Sequential transcriptional waves and NF-κB-driven chromatin remodeling direct drug-induced dedifferentiation in cancer.
PMID 41986344 · PMC13083995 · Nature communications · 2026 · 8 claims · 8 setups
BRAFi (vemurafenib) treatment drives BRAF-mutant melanoma cells through a reversible dedifferentiation transition from a melanocytic state through a neural crest-like state to a drug-tolerant mesenchymal state